Predictors of response to opicinumab in acute optic neuritis

D Cadavid, L Balcer, S Galetta, O Aktas, T Ziemssen, LJ Vanopdenbosch, L Leocani, MS Freedman, GT Plant, JL Preiningerova, F Ziemssen, L Massacesi, Y Chai, L Xu, on behalf of the RENEW Study Investigators

Research output: Contribution to journalArticle

Abstract

Objective: The objective of this study was to evaluate prespecified and post hoc analyses in RENEW subgroups to identify participants more likely to benefit from opicinumab. Methods: RENEW assessed the efficacy/safety of opicinumab versus placebo in participants with a first unilateral acute optic neuritis (AON) episode. Difference in visual evoked potential (VEP) latency of the affected eye at 24 weeks versus the fellow eye at baseline was the primary endpoint. Interactions between the primary endpoint and prespecified baseline variables (including age, timing of treatment initiation, and visual impairment) using the median as cut-off were evaluated in the per protocol population using analysis of covariance (ANCOVA); subgroups based on preexisting brain T2 lesion volume were also analyzed. Interactions between the primary endpoint and retinal ganglion cell layer/inner plexiform layer (RGCL/IPL) and retinal nerve fiber layer (RNFL) thickness were assessed post hoc as was weight gain by treatment. Results: Treatment benefit of opicinumab (n = 33) over placebo (n = 36) on the primary endpoint was greatest in participants older than the median age at baseline (≥33 years); the difference versus placebo for baseline age ≥33 years was −14.17 msec [P = 0.01] versus −0.89 msec for baseline age
Original languageEnglish
Pages (from-to)1154-1162
Number of pages9
JournalAnnals of Clinical and Translational Neurology
Volume5
Issue number10
DOIs
Publication statusPublished - 2018

Fingerprint

Optic Neuritis
Placebos
Visual Evoked Potentials
Retinal Ganglion Cells
Vision Disorders
Nerve Fibers
Weight Gain
Therapeutics
Safety
Brain
Population

Cite this

Cadavid, D., Balcer, L., Galetta, S., Aktas, O., Ziemssen, T., Vanopdenbosch, LJ., ... Investigators, O. B. O. T. RENEW. S. (2018). Predictors of response to opicinumab in acute optic neuritis. Annals of Clinical and Translational Neurology, 5(10), 1154-1162. https://doi.org/10.1002/acn3.620

Predictors of response to opicinumab in acute optic neuritis. / Cadavid, D; Balcer, L; Galetta, S; Aktas, O; Ziemssen, T; Vanopdenbosch, LJ; Leocani, L; Freedman, MS; Plant, GT; Preiningerova, JL; Ziemssen, F; Massacesi, L; Chai, Y; Xu, L; Investigators, on behalf of the RENEW Study.

In: Annals of Clinical and Translational Neurology, Vol. 5, No. 10, 2018, p. 1154-1162.

Research output: Contribution to journalArticle

Cadavid, D, Balcer, L, Galetta, S, Aktas, O, Ziemssen, T, Vanopdenbosch, LJ, Leocani, L, Freedman, MS, Plant, GT, Preiningerova, JL, Ziemssen, F, Massacesi, L, Chai, Y, Xu, L & Investigators, OBOTRENEWS 2018, 'Predictors of response to opicinumab in acute optic neuritis', Annals of Clinical and Translational Neurology, vol. 5, no. 10, pp. 1154-1162. https://doi.org/10.1002/acn3.620
Cadavid D, Balcer L, Galetta S, Aktas O, Ziemssen T, Vanopdenbosch LJ et al. Predictors of response to opicinumab in acute optic neuritis. Annals of Clinical and Translational Neurology. 2018;5(10):1154-1162. https://doi.org/10.1002/acn3.620
Cadavid, D ; Balcer, L ; Galetta, S ; Aktas, O ; Ziemssen, T ; Vanopdenbosch, LJ ; Leocani, L ; Freedman, MS ; Plant, GT ; Preiningerova, JL ; Ziemssen, F ; Massacesi, L ; Chai, Y ; Xu, L ; Investigators, on behalf of the RENEW Study. / Predictors of response to opicinumab in acute optic neuritis. In: Annals of Clinical and Translational Neurology. 2018 ; Vol. 5, No. 10. pp. 1154-1162.
@article{e81d1e7eacfb401582e31447ae738e5f,
title = "Predictors of response to opicinumab in acute optic neuritis",
abstract = "Objective: The objective of this study was to evaluate prespecified and post hoc analyses in RENEW subgroups to identify participants more likely to benefit from opicinumab. Methods: RENEW assessed the efficacy/safety of opicinumab versus placebo in participants with a first unilateral acute optic neuritis (AON) episode. Difference in visual evoked potential (VEP) latency of the affected eye at 24 weeks versus the fellow eye at baseline was the primary endpoint. Interactions between the primary endpoint and prespecified baseline variables (including age, timing of treatment initiation, and visual impairment) using the median as cut-off were evaluated in the per protocol population using analysis of covariance (ANCOVA); subgroups based on preexisting brain T2 lesion volume were also analyzed. Interactions between the primary endpoint and retinal ganglion cell layer/inner plexiform layer (RGCL/IPL) and retinal nerve fiber layer (RNFL) thickness were assessed post hoc as was weight gain by treatment. Results: Treatment benefit of opicinumab (n = 33) over placebo (n = 36) on the primary endpoint was greatest in participants older than the median age at baseline (≥33 years); the difference versus placebo for baseline age ≥33 years was −14.17 msec [P = 0.01] versus −0.89 msec for baseline age",
author = "D Cadavid and L Balcer and S Galetta and O Aktas and T Ziemssen and LJ Vanopdenbosch and L Leocani and MS Freedman and GT Plant and JL Preiningerova and F Ziemssen and L Massacesi and Y Chai and L Xu and Investigators, {on behalf of the RENEW Study}",
year = "2018",
doi = "10.1002/acn3.620",
language = "English",
volume = "5",
pages = "1154--1162",
journal = "Annals of Clinical and Translational Neurology",
issn = "2328-9503",
publisher = "Wiley-Blackwell",
number = "10",

}

TY - JOUR

T1 - Predictors of response to opicinumab in acute optic neuritis

AU - Cadavid, D

AU - Balcer, L

AU - Galetta, S

AU - Aktas, O

AU - Ziemssen, T

AU - Vanopdenbosch, LJ

AU - Leocani, L

AU - Freedman, MS

AU - Plant, GT

AU - Preiningerova, JL

AU - Ziemssen, F

AU - Massacesi, L

AU - Chai, Y

AU - Xu, L

AU - Investigators, on behalf of the RENEW Study

PY - 2018

Y1 - 2018

N2 - Objective: The objective of this study was to evaluate prespecified and post hoc analyses in RENEW subgroups to identify participants more likely to benefit from opicinumab. Methods: RENEW assessed the efficacy/safety of opicinumab versus placebo in participants with a first unilateral acute optic neuritis (AON) episode. Difference in visual evoked potential (VEP) latency of the affected eye at 24 weeks versus the fellow eye at baseline was the primary endpoint. Interactions between the primary endpoint and prespecified baseline variables (including age, timing of treatment initiation, and visual impairment) using the median as cut-off were evaluated in the per protocol population using analysis of covariance (ANCOVA); subgroups based on preexisting brain T2 lesion volume were also analyzed. Interactions between the primary endpoint and retinal ganglion cell layer/inner plexiform layer (RGCL/IPL) and retinal nerve fiber layer (RNFL) thickness were assessed post hoc as was weight gain by treatment. Results: Treatment benefit of opicinumab (n = 33) over placebo (n = 36) on the primary endpoint was greatest in participants older than the median age at baseline (≥33 years); the difference versus placebo for baseline age ≥33 years was −14.17 msec [P = 0.01] versus −0.89 msec for baseline age

AB - Objective: The objective of this study was to evaluate prespecified and post hoc analyses in RENEW subgroups to identify participants more likely to benefit from opicinumab. Methods: RENEW assessed the efficacy/safety of opicinumab versus placebo in participants with a first unilateral acute optic neuritis (AON) episode. Difference in visual evoked potential (VEP) latency of the affected eye at 24 weeks versus the fellow eye at baseline was the primary endpoint. Interactions between the primary endpoint and prespecified baseline variables (including age, timing of treatment initiation, and visual impairment) using the median as cut-off were evaluated in the per protocol population using analysis of covariance (ANCOVA); subgroups based on preexisting brain T2 lesion volume were also analyzed. Interactions between the primary endpoint and retinal ganglion cell layer/inner plexiform layer (RGCL/IPL) and retinal nerve fiber layer (RNFL) thickness were assessed post hoc as was weight gain by treatment. Results: Treatment benefit of opicinumab (n = 33) over placebo (n = 36) on the primary endpoint was greatest in participants older than the median age at baseline (≥33 years); the difference versus placebo for baseline age ≥33 years was −14.17 msec [P = 0.01] versus −0.89 msec for baseline age

U2 - 10.1002/acn3.620

DO - 10.1002/acn3.620

M3 - Article

VL - 5

SP - 1154

EP - 1162

JO - Annals of Clinical and Translational Neurology

JF - Annals of Clinical and Translational Neurology

SN - 2328-9503

IS - 10

ER -